The intersection between host-pathogen interactions and metabolism during Vibrio cholerae infection.


Journal

Current opinion in microbiology
ISSN: 1879-0364
Titre abrégé: Curr Opin Microbiol
Pays: England
ID NLM: 9815056

Informations de publication

Date de publication:
Feb 2024
Historique:
received: 15 11 2023
revised: 19 12 2023
accepted: 19 12 2023
medline: 11 2 2024
pubmed: 13 1 2024
entrez: 12 1 2024
Statut: ppublish

Résumé

Vibrio cholerae (V. cholerae), the etiological agent of cholera, uses cholera toxin (CT) to cause severe diarrheal disease. Cholera is still a significant cause of mortality worldwide with about half of all cholera cases and deaths occurring in children under five. Owing to the lack of cost-effective vaccination and poor vaccine efficacy in children, there is a need for alternative preventative and therapeutic strategies. Recent advances in our knowledge of the interplay between CT-induced disease and host-pathogen metabolism have opened the door for investigating how modulation of intestinal metabolism by V. cholerae during disease impacts host intestinal immunity, the gut microbiota, and pathogen-phage interactions. In this review article, we examine recent progress in our understanding of host-pathogen interactions during V. cholerae infection and discuss future work deciphering how modulation of gut metabolism during cholera intersects these processes to enable successful fecal-oral transmission of the pathogen.

Identifiants

pubmed: 38215547
pii: S1369-5274(23)00158-3
doi: 10.1016/j.mib.2023.102421
pii:
doi:

Substances chimiques

Cholera Toxin 9012-63-9

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102421

Subventions

Organisme : NIGMS NIH HHS
ID : K12 GM068524
Pays : United States

Informations de copyright

Published by Elsevier Ltd.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare no competing interests.

Auteurs

Sedelia R Dominguez (SR)

Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Molecular Biology, School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.

Phillip N Doan (PN)

Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Molecular Biology, School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA.

Fabian Rivera-Chávez (F)

Division of Host-Microbe Systems and Therapeutics, Department of Pediatrics, University of California, San Diego, La Jolla, CA, USA; Department of Molecular Biology, School of Biological Sciences, University of California, San Diego, La Jolla, CA, USA. Electronic address: fcrivera@health.ucsd.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH